Berzigotti Annalisa, Rinaldi Maria Francesca, Magalotti Donatella, Morelli Maria Cristina, Zappoli Paola, Andreone Pietro, Rossi Cristina, Zoli Marco
Dipartimento di Medicina Interna, Cardioangiologia, Epatologia, Policlinico S. Orsola-Malpighi, Via Albertoni 15, 40138 Bologna, Italy.
J Hepatol. 2006 Feb;44(2):310-6. doi: 10.1016/j.jhep.2005.10.015. Epub 2005 Nov 14.
BACKGROUND/AIMS: We aimed to characterize by echo-color-Doppler the splanchnic hemodynamics of patients good and poor responders to primary prophylaxis with nadolol.
Thirty cirrhotic patients (Child-score 7.0+/-1.8) with medium/large esophageal varices without previous bleedings were consecutively enrolled. At inclusion and after 3 months of treatment with nadolol, they underwent a splanchnic echo-color-Doppler study and a measurement of hepatic venous pressure gradient (HVPG).
Nadolol (60+/-36 mg/day; range 20-160) induced a significant reduction of HVPG (16.6+/-6.1 vs. 19.4+/-4.6 mmHg, P < 0.0001). 13 patients (43.3%) were hemodynamic responders. Responders and Poor-responders had similar baseline clinical characteristics. Poor-responders at baseline were characterized by lower impedance indexes in superior mesenteric artery (SMA) (PI 2.29+/-0.45 vs. 2.74+/-0.46; P = 0.01; RI 0.83+/-0.04 vs. 0.86+/-0.03; P = 0.02), hepatic artery (HA) (PI 1.41+/-0.19 vs. 1.79+/-0.48; P = 0.03; RI 0.71+/-0.05 vs. 0.80+/-0.07; P = 0.02), and splenic artery (SA) (PI 1.18+/-0.27 vs. 1.73+/-0.40; P = 0.01; RI 0.66+/-0.07 vs. 0.73+/-0.09; P = 0.02), and by higher mean flow velocity of HA (52.6+/-21.6 vs. 26.5+/-9.5 cm/s; P = 0.02) and SMA (49.7+/-14.5 vs. 33.9+/-13.1 cm/s; P = 0.06).
Cirrhotic patients poor-responders to nadolol show a pronounced arterial splanchnic vasodilatation at a baseline echo-color-Doppler study. This can be considered a non-invasive clue for the a priori identification of this subgroup of patients.
背景/目的:我们旨在通过彩色多普勒超声对纳多洛尔一级预防反应良好和反应不佳的患者的内脏血流动力学进行特征分析。
连续纳入30例肝硬化患者(Child评分7.0±1.8),这些患者有中/大型食管静脉曲张且既往未出血。在纳入时及接受纳多洛尔治疗3个月后,他们接受了内脏彩色多普勒超声检查和肝静脉压力梯度(HVPG)测量。
纳多洛尔(60±36毫克/天;范围20 - 160)使HVPG显著降低(16.6±6.1对19.4±4.6毫米汞柱,P < 0.0001)。13例患者(43.3%)为血流动力学反应者。反应者和无反应者具有相似的基线临床特征。基线时无反应者的特征为肠系膜上动脉(SMA)、肝动脉(HA)和脾动脉(SA)的阻抗指数较低,以及HA和SMA的平均流速较高。
在基线彩色多普勒超声检查中,对纳多洛尔反应不佳的肝硬化患者表现出明显的内脏动脉血管扩张。这可被视为对该亚组患者进行先验识别的非侵入性线索。